CFDE Data Portal | Search NDUFA3

	Label	Description
	NDUFA3 Gene (Entity type)	ENSG00000170906 - NADH:ubiquinone oxidoreductase subunit A3
	NDUFA3 associations Collection (Entity type)	Associations for NDUFA3_associations
	NDUFA3 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	GSE134191 3 V 1 METFORMIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE120210 GSE120214 TBXT brachyury inhibition 4 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE168745 H-7 JHH-7 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE158456 2 V 3 FURIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE255432 7 V 3 IMEGLIMIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE104022 1 V 0 TAMOXIFEN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS

NDUFA3

ENSG00000170906 - NADH:ubiquinone oxidoreductase subunit A3

NDUFA3 associations

Associations for NDUFA3_associations

NDUFA3 associations.tsv

A file from IDG as part of the Harmonizome project

GSE134191 3 V 1 METFORMIN MOUSE DN

A Gene Set from LINCS

GSE120210 GSE120214 TBXT brachyury inhibition 4 v 0 human dn

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn

A Gene Set from LINCS

GSE168745 H-7 JHH-7 0 v 1 human dn

A Gene Set from LINCS

GSE158456 2 V 3 FURIN MOUSE DN

A Gene Set from LINCS

GSE255432 7 V 3 IMEGLIMIN MOUSE DN

A Gene Set from LINCS

GSE104022 1 V 0 TAMOXIFEN MOUSE DN

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.